Dr. Halmos on the Impact of EGFR Inhibitors on the Treatment of Lung Cancer

Balazs Halmos, MD
Published: Monday, Apr 28, 2014

Balazs Halmos, MD, section chief of Thoracic Oncology at New York-Presbyterian Hospital/Columbia University Medical Center, discusses the impact of EGFR inhibitors on the treatment of lung cancer.

It is now widely recognized that a proportion of patients with lung cancer (about 10% in the U.S.) carry an EGFR mutation. This discovery has transformed the way the disease is treated.

EGFR inhibitors extend survival and are less toxic than chemotherapies, Halmos says​. Previously, life expectancy was 12 months in this population; now, it is about 3 years. EGFR inhibitors have changed the entire mindset of how to treat lung cancer.

Balazs Halmos, MD, section chief of Thoracic Oncology at New York-Presbyterian Hospital/Columbia University Medical Center, discusses the impact of EGFR inhibitors on the treatment of lung cancer.

It is now widely recognized that a proportion of patients with lung cancer (about 10% in the U.S.) carry an EGFR mutation. This discovery has transformed the way the disease is treated.

EGFR inhibitors extend survival and are less toxic than chemotherapies, Halmos says​. Previously, life expectancy was 12 months in this population; now, it is about 3 years. EGFR inhibitors have changed the entire mindset of how to treat lung cancer.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x